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Abstract
The C-terminal 42 kDa fragments of the P. falciparum Merozoite Surface Protein 1, MSP1-42 is a leading malaria vaccine
candidate. MSP1-33, the N-terminal processed fragment of MSP1-42, is rich in T cell epitopes and it is hypothesized that they
enhance antibody response toward MSP1-19. Here, we gave in vivo evidence that T cell epitope regions of MSP1-33 provide
functional help in inducing anti-MSP1-19 antibodies. Eleven truncated MSP1-33 segments were expressed in tandem with
MSP1-19, and immunogenicity was evaluated in Swiss Webster mice and New Zealand White rabbits. Analyses of anti-MSP1-
19 antibody responses revealed striking differences in these segments’ helper function despite that they all possess T cell
epitopes. Only a few fragments induced a generalized response (100%) in outbred mice. These were comparable to or
surpassed the responses observed with the full length MSP1-42. In rabbits, only a subset of truncated antigens induced
potent parasite growth inhibitory antibodies. Notably, two constructs were more efficacious than MSP1-42, with one
containing only conserved T cell epitopes. Moreover, another T cell epitope region induced high titers of non-inhibitory
antibodies and they interfered with the inhibitory activities of anti-MSP1-42 antibodies. In mice, this region also induced a
skewed TH2 cellular response. This is the first demonstration that T cell epitope regions of MSP1-33 positively or negatively
influenced antibody responses. Differential recognition of these regions by humans may play critical roles in vaccine
induced and/or natural immunity to MSP1-42. This study provides the rational basis to re-engineer more efficacious MSP1-
42 vaccines by selective inclusion and exclusion of MSP1-33 specific T cell epitopes.
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Introduction
The C-terminal fragments of the Merozoite Surface Protein 1
(MSP1) of P. falciparum, MSP1-42, is one of the leading candidates
for a blood-stage malaria vaccine [1]. MSP1 is a 195kDa protein
that is proteolytically processed during schizogony into four
smaller fragments: 83 kDa, 30 kDa, 38 kDa, and 42 kDa [2,3].
The C-terminal 42 kDa protein is then further processed during
merozoite invasion into a 33 kDa and a 19 kDa fragment [3]. The
19 kDa fragment (MSP1-19) is carried into the infected erythro-
cyte by the merozoites, while the 33 kDa fragment (MSP1-33) is
released into the blood plasma [4]. Protective immunity induced
by MSP1-42/MSP1-19 has been shown to be antibody mediated
[5,6,7,8,9]. Passive transfers of anti-MSP1-42 or MSP1-19
monoclonal and polyclonal antibodies have protected against
malaria [10,11,12,13,14,15]; MSP1-42 or MSP1-19 specific
antibodies may act by inhibiting merozoite invasion [9]. On the
other hand, blocking antibodies specific for MSP1-42/MSP1-19
have also been detected, and these antibodies interfere with the
activities of parasite inhibitory anti-MSP1-19 antibodies [16].
Vaccination studies with MSP1-42 or MSP1-19 have demonstrat-
ed strong or complete protection against blood infections in rodent
and monkey models [17,18,19,20,21]. Monkeys protected by
MSP1-42 vaccinations produce parasite inhibitory antibodies
[17,19,20], thus suggesting that vaccine-induced immunity is also
antibody mediated.
Although the above studies have convincingly demonstrated the
vaccine potential of MSP1-42/MSP1-19, a Phase II clinical trial
using MSP1-42 resulted in no in vivo protection [22]. The inability
of the MSP1-42 vaccine formulation to induce protection in this
clinical trial could be attributed to very low levels (titers) of parasite
inhibitory antibodies [22,23]. Two Phase I trials of MSP1-42 using
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inhibitory antibodies [24,25]. The failure to elicit protective
immunity and/or high levels of parasite inhibitory antibodies in
these clinical trials may be attributed to a number of factors: a)
serum samples from vaccinated individuals have no parasite
inhibitory effects suggesting that the MSP1-42 vaccine induced
antibodies of the wrong specificity [22,24]: b) the magnitude of
antibody titers induced by the MSP1-42 vaccines were not high
enough to have biological activities [23,24,26]: c) antibodies were
relatively short-lived to confer protection [22,25]: and d)
inadequate induction of memory responses [27]. A better
understanding of the vaccine-induced immune response to
MSP1-42 may help to overcome these shortcomings and may
help to design a more efficacious MSP1-42 vaccine.
Unlike MSP1-42/MSP1-19, there have been few studies on
MSP1-33. Studies on MSP1-33 primarily focus on mining T cell
epitopes [28,29,30] since it has been shown that MSP1-19 does
not possess adequate T helper epitopes to stimulate antibody
response in a diverse genetic population [29,31]. Thus, it has
been suggested that these T cell epitopes on MSP1-33 may
provide cognate helper function specific for anti-MSP1-19
antibody response [29,30,31,32,33,34]. It is assumed that
MSP1-33 specific T cell epitopes will all contribute positively to
the induction of biologically active anti-MSP1-19 antibodies.
However, it has been well established in other model systems that
T cell epitopes can influence the development antibody response
to B cell epitopes [35,36,37,38]. Indeed, previous studies have
observed differences in antibody specificity induced by MSP1-19
versus MSP1-42 (ie. MSP1-33 + MSP1-19) [39]. In a genetically
diverse population, MSP1-42 is more effective in inducing
parasite growth inhibitory antibody responses than MSP1-19
[39]. In addition, in vivo protection induced by MSP1-19 is also
regulated by the host’s immune response, (IR) genes [31,33].
Moreover, MSP1-42 induce antibodies that are more broadly
cross-reactive with other allelic forms of MSP1-19 than the
MSP1-19 fragment [39], suggesting that MSP1-42 may elicit
antibodies to additional epitopes [39]. It is possible that MSP1-
33, which harbors abundant T cell epitopes, may influence
antibody responses induced by MSP1-42. To address this
hypothesis, we investigated the ability of T cell epitopes of
MSP1-33 to provide help, and whether they can critically
influence antibody specificity. Outbred Swiss Webster mice were
used to examine the efficacy of eleven recombinant MSP1-42
proteins consisting of truncated segments of MSP1-33 linked to
MSP1-19. Additionally, the recombinant subunit proteins,
formulated with ISA51, were evaluated in New Zealand White
(NZW) rabbits for the induction of parasite growth inhibitory
antibodies. Results showed that T cell epitopes of MSP1-33 have
a profound influence on MSP1-42 vaccine efficacy.
Materials and Methods
Ethics Statement
All experiments involving animals (mice and rabbits) were
approved by the University of Hawaii Institutional Animal Care
and Use Committee (IACUC). Procedures were designed to inflict
minimum pain and distress as possible. The use of animals in
experimentation was strictly adhered to the "Guide for the Care
and Use of Laboratory Animals" published by the Institute for
Laboratory Animal Research (ILAR). Immunized animals were
monitored for unusual pain and distress and they would have been
euthanized if such symptoms appeared. Euthanasia was performed
according to the methods recommended by the American
Veterinary Medical Association (AVMA). University of Hawaii’s
Animal Care Assurance number is A3423-01. For all animal
studies, the IACUC approved specific protocol number is 08-389.
Mouse and Rabbit strains
Outbred Swiss Webster mice (female, 6–8 weeks old) were
obtained from four different vendors, Taconic (Albany, NY),
Simonsen (San Clara, CA), Harlan Spraque Dawley Inc.
(Indianapolis, IA), and Charles River Laboratory (Wilmington,
MA) to ensure genetic heterogeneity. New Zealand White (NZW)
rabbits (female, 8–10 lbs) were obtained from Western Oregon
Rabbit Company (Philomath, Oregon). The use of mice and
rabbits were approved by the University of Hawaii’s Institutional
Animal Care and Use Committee.
MSP1-specific antibody assays
Mouse and rabbit sera were assayed for anti-MSP1 antibodies
(MSP1-42 and MSP1-19) by direct binding ELISAs as previously
described [40]. Recombinant MSP1-42 and MSP1-42 antigens
used for coating ELISA plates were produced based on P.
falciparum FUP strain and were obtained from previous studies.
The MSP1-42 was expressed in baculovirus [33],and, MSP1-19
was expressed in yeast [32]. Recombinant MSP1-33 was expressed
in E.coli and was based on the 3D7 strain, which has identical
MSP1-33 sequence as FUP [41]. Briefly, 96-well ELISA plates
(Costar, Acton, MA) were coated with the appropriate test antigen
at a concentration of 0.4 mg/mL. Plates were then blocked with
1% Bovine Serum Albumin (BSA) in Borate Buffered Saline (BBS).
Test sera were serially diluted in 1% BSA/0.5% yeast extract/BBS
and then incubated for 60 minutes in the antigen-coated ELISA
wells. Wells were washed seven times with High Salt Borate
Buffered Saline (HSBBS) and incubated for 60 minutes with
horseradish peroxidase conjugated anti-rabbit (H & L chain
specific, Kirkgaard and Perry Laboratories, Gaithersburg, MD) at
a dilution of 1:2000 or anti-mouse antibodies (H & L chain
specific, Kirkgaard and Perry Laboratories, Gaithersburg, MD) at
a dilution of 1:2000. Wells were subsequently washed as above and
color development was made using the peroxidase substrates,
H2O2 and 2.29-azinobis (3-ethylbenzthiazolinesulfonic acid)/
ABTS (Kirkgaard and Perry Laboratories, Gaithersburg, MD).
Optical density (O.D.) was determined at 405 nm and endpoint
titers were calculated and graphed using Sigma Plot 10. End point
titers were calculated using the serum dilutions that gave an O.D.
of 0.2, which is greater than 4 fold of background O.D.
absorbance obtained using normal mouse or rabbit serum.
Expression and purification of recombinant MSP1 C-
terminal subunit proteins in Drosophila S2 cell
The recombinant MSP1 C-terminal subunit proteins were
produced in the Drosophila S2 expression system. The expression
system consists of the Drosophila S2 cells [42] and a series of broad
host plasmid vectors that directed the expression of heterologous
proteins [43]. The expression plasmid, pMttbns (derived from
pMttPA) contains the following elements: Drosophila melanogaster
metallothionein promoter, the human tissue plasminogen activator
secretion leader (tPAL) and the SV40 early polyadenylation signal.
A 14 base pair BamHI fragment was excised from the pMttbns
vector to yield pMttDXho creating a unique XhoI. This
expression vector results in the secretion of the target protein into
the culture medium. The MSP-1 sequences were introduced into
the pMttDXho vector using the unique BglII and XhoI sites.
Eleven constructs, referred hereto as Constructs 33-A – 33-K,
were designed to express regions of MSP1-33 fused to MSP1-19
(Figure 1). These constructs were selected based on T-cell epitope
MSP1-33 T Cell Epitopes Affect Vaccine Efficacy
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empirically by antigen driven human PBMC proliferation assays
[28,29,30]. Table 1 shows the amino acid sequence of the
identified and predicted T cell epitopes used in the design of the
Constructs 33-A – 33-K. For the construction of Constructs 33-A
– 33-K expression plasmids, two strategies were used either
separately or in combination. The first strategy utilized PCR
amplified DNA sequences encoding T cell epitope regions from
the MSP1-42 fragment that was derived from the FUP strain
genomic DNA (Table 2). The second strategy utilized oligonucle-
otides encoding for the entire T cell epitope fragment(s) (Table 2).
All PCR and oligonucleotide generated MSP1 C-terminal subunit
gene fragments were designed to include restriction endonuclease
sites (BamHI and XhoI) that were used for cloning.
S2 cells were cultured in Excel 420 serum free medium (SAFC,
St. Louis, MO). The cells were co-transformed with the
pMttDXho-MSP1 expression plasmids and the pCoHygro selec-
tion plasmid, which encodes hygromycin resistance utilizing the
calcium phosphate co-precipitation method (Invitrogen Kit,
Carlsbad, CA) according to the manufacturer’s recommendations.
Cells were co-transformed with 20 mg total DNA with a 20:1 ratio
of expression plasmid to selection plasmid. Transformants were
selected with hygromycin B (Roche Molecular Biochemicals,
Indianapolis, IN) at 300 mg/mL. For expression studies, cells were
induced with 200 mM CuSO4. The recombinant proteins were
purified from the culture supernatant by immunoaffinity chroma-
tography utilizing the mAb 5.2 [45], and analyzed by SDS-PAGE.
Immunization with recombinant truncated MSP1-42
subunit proteins
Swiss Webster mice were divided into 11 different vaccination
groups (12micepergroup).Each mousegroup was immunized with
a different truncated MSP1-42 construct and two control groups
were immunized with either MSP1-19 or MSP1-42. All mice were
immunized three times at 21 days intervals, via the IP route. The
first immunization consisted of a sub-optimal dose of 2 mg antigen,
followedbytwoboosterinjectionswithanoptimaldoseof5 mg[46].
The immunogens were emulsified in Complete Freund’s Adjuvant
Figure 1. Aligned amino acid sequences of the eleven truncated MSP1-42 subunit protein constructs compared to MSP1-42. All
constructs contain the MSP1-19 fragment (not shown) at the C-terminal end.
doi:10.1371/journal.pone.0024782.g001
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Adjuvant (IFA) for booster injections. Sera were obtained through
tail bleeds, 14 days after each immunization.
New Zealand White rabbits were divided into 10 different
immunization groups (3 rabbits per group). NZW rabbits were
immunized with S2 cell expressed recombinant truncated MSP1-
42 proteins formulated in Montanide ISA51 adjuvant. Each dose
of vaccine composed of 50 mg of antigen in 250 ml PBS, and was
emulsified with an equal volume of ISA51 as per the manufac-
turer’s recommendations. The emulsion was injected, via the IM
route, into the left and right thighs. A total of four immunizations
were given at 4 weeks intervals and sera collected 21 days after the
last immunization were used in ELISAs and parasite growth
inhibition assays. As control, rabbits were similarly immunized
with S2 cell expressed full length MSP1-42.
ELISPOT Assay
ELISPOTS of splenocytes from immunized mice were
performed according to methods previously described [47].
Ninety-six well PVDF plates (Millipore Inc., Bedford, MA) were
coated with 10 ug/mL of anti-IFN-c mAb (R4-642) and 5 ug/mL
of anti-IL-4 mAb (11B11) (BD Biosciences, San Diego, CA) and
incubated overnight at room temperature. Plates were then
washed five times with sterile phosphate buffered saline (PBS)
and blocked for 60 minutes at 37uC with DMEM/10% fetal
bovine serum. Mice from each vaccination group were sacrificed
by cervical dislocation, the spleen removed, and placed in DMEM.
The spleen was crushed and individual suspensions of splenocytes
were prepared by passing through a cell strainer and washing four
times in DMEM. Splenocytes were plated at 0.5610
6 cells/well,
0.25610
6 cells/well, and 0.125610
6 cells/well, and the corre-
sponding recombinant immunogen was added at a final
concentration of 20 ug/mL as the stimulating antigen. Positive
control wells were incubated with 5 ng/mL of phorbol myristate
acetate (PMA) and 1 ng/mL ionomycin. Plates were incubated
again at 37uC for 48 hours and then processed by washing four
times with PBS and five times with PBS with 0.05% Tween-20.
Biotinylated monoclonal antibodies against IFN-c at 2 mg/mL
(XMG1.2), and monoclonal antibodies against IL-4 at 1 mg/mL
(BVD6-24G2) (BD, Biosciences, San Diego, CA) were added to
appropriate wells and incubated for three hours at 37uC. Plates
were again washed as mentioned above and incubated with
peroxidase conjugated streptavidin (Kirkgaard and Perry Labora-
tories, Gaithersburg, MD) for 60 minutes at a concentration of
1:800. After seven washings, plates were developed with a solution
consisting of 3,39-Diaminobenzidine tetrahydrochloride (DAB)
(Sigma-Aldrich St. Louis, MO, 1 mg/ml) and 30% H2O2 (Sigma-
Aldrich St. Louis, MO). Cytokine producing cells were counted
microscopically and data presented as spot-forming-units (SFU)
per million of plated splenocytes.
In vitro parasite growth inhibition assays
The ability of rabbit sera generated by immunization with each
of the nine truncated MSP1-42 subunit proteins to inhibit parasite
growth was determined using an in vitro assay [20,32,48,49]. The
inhibition assay was performed using sorbitol synchronized
parasite cultures (3D7 strain) as described [32]. Synchronized
parasite cultures at a starting parasitemia of 0.2% and 0.8%
hematocrit were incubated in 30% heat inactivated immune sera.
Cultures were then incubated for 72 hours with periodic mixing.
Parasitemia was then determined microscopically by Giemsa
staining. The degree of parasite growth inhibition was determined
by comparing the parasitemias of cultures incubated with pre-
immune sera as previously described [32,48,49].
In vitro assay for blocking antibodies
To test for the presence of blocking antibodies that interfere with
anti-MSP1 growth inhibitory antibodies, synchronized parasite
cultures were incubated in a mixture of 20% heat inactivated anti-
Construct 33-C sera and 15% anti-MSP1-42 inhibitory sera as
previously described [50]. Normal rabbit sera were similarly mixed
with the inhibitory anti-MSP1-42 sera as control. The inhibitory
anti-MSP1-42 sera was obtained from a previous vaccination study
[39]. In that study we produced highly inhibitory anti-MSP1-42
antibodies (.90% growth inhibition) by hyper-immunization of
rabbitswith full length MSP1-42 emulsified inCFA[39].Thesesera
were used because of their very high levels of parasite growth
inhibition making their inhibitory activities less prone to dilution
effects when mixing with other sources of rabbit sera.
Data handling and Statistics
Sigma Plot 10H and GraphPadPrism 4H were used to calculate
end point titers. One-way Analysis of Variance (ANOVA) and
Table 1. Sequence and location of previously identified and
predicted T cell epitopes in truncated Constructs 33-A - 33-K.
MSP1-33 Amino Acid
Position N-base # Amino Acid Sequence
Identified T cell epitopes
1 3-19 SVTMDNILSGFENEYDV
2 22-38 LKPLAGVYRSLKKQIEK
3 37-54 EKNIFTFNLNLNDILNSR
4 81-95 IIEDSFKLLNSEQKN
5 118-134 GISYYEKVLAKYKDDLE
6 127-145 AKYKDDLESIKKVIKEEKE
7 175-191 TNIETLYNNLVNKIDDY
8 190-202 DYLINLKAKINDS
9 210-223 HVKITKLSDLKAID
10 225-244 KIDLFKNHNDFDAIKKLIND
11 252-270 GKLLSTGLVQNFPNTIISK
12 257-275 TGLVQNFPNTIISKLIEGK
13 263-275 FPNTIISKLIEGKFQDML
Predicted T cell epitopes
14 22-30 LKPLAGVYR
15 69, 128-135 LKYKSDLDS
16 170-178 YLPFLNNIE
17 9-11, 21-26 ILSYLKPLA
18 29-35, 49-50 YRSLKKQDI
19 174-181 LNNIETLY
20 32-35, 49-53 LKKQDILNS
21 65-69, 128-131 LESDLKYKS
22 177-181 IETLY
23 50-54, 64-67 ILNSRVLES
24 19-37 VIYLKPLAGVYRSLKKQIE
25 43-56 FNLNLNDILNSRLK
26 69-85 LMQFKHISSNEYIIEDS
27 170-189 FLPFLTNIETLYNNLVNKID
28 180-201 LYNNLVNKIDDYLINLKAKIND
doi:10.1371/journal.pone.0024782.t001
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antibody titers amongst the different test groups. Cytokine
responses (ELISPOT) in mice and parasite growth inhibition by
different anti-truncated MSP1-42 sera were analyzed by Logistic
Regression for Repeated Measures and Fisher Exact Test:
respectively (IBM SPSS Statistics). A p,0.05 was considered
statistically significant.
Results
Expression of recombinant proteins
Induced culture supernatants from Drosophila S2 cells trans-
formed with Construct 33-A – 33-K were clarified and the
recombinant proteins were purified by immuno-affinity chroma-
tography. The purified proteins were analyzed by SDS-PAGE. A
representative reducing gel of the purified proteins is shown in
Figure 2. A protein doublet was observed after purification of
Construct 33-A (,19 kDa) and 33-B (,21 kDa) (Figure 2, Lanes 1
and 2), which may result from different degrees of glycosylation in
the insect cells. A single protein band was observed after
purification of Construct 33-C – 33-K, with molecular sizes of
,14, 29, 32, 39, 21, 19, 17, 21, and 19 kDa; respectively (Figure 2,
Lanes 3-11). All truncated MSP1 C-terminal recombinant subunit
proteins maintained native-like conformation based on binding
with conformationally sensitive monoclonal antibodies. As exam-
ples, Construct 33-A, 33-B, and 33-C were reactive to MSP1-19
Table 2. Primer Sequences for the Construction of Truncated MSP1-42 Constructs.
Construct
MSP1-33 (Amino
Acid Position, NRC) Primers/Oligonucleotides
33-A 209-280 F: acgtacggatccgttggcggtggtaccGCACATGTTAAAATAACTAAAC
R: agtacaatctcgagttactaACTGCAGAAAATACCATCGAAAAGTG
33-B 22-38 F: aaagttggcggtggtaccGCACATGTTAAAATAACTAAAC
R: agtacaatctcgagttactaACTGCAGAAAATACCATCGAAAAGTG
209-280 F: acgtacggatccgttggcggtggtaccGCACATGTTAAAATAACTAAAC
R: agtacaatctcgagttactaACTGCAGAAAATACCATCGAAAAGTG
33-C 250-280 F: acgtacggatccgttggcggtggtaccATGCTTGGCAAATTACTTAG
R: agtacaatctcgagttactaACTGCAGAAAATACCATCGAAAAGTG
33-D 76-280 F: tagcggatccACACTTTTAAAAAGTTACAAA
R: agtacaatctcgagttactaACTGCAGAAAATACCATCGAAAAGTG
33-E 1-252 F: gtcgactagtatgGCAATATCTGTCACAATGGAT
R: gctacggccatggcggcggcggcggTTCGTATAGAAAAAAGCA
33-F 1-20 F: actagtatgGCAATATCTGTCACAATGGATAATATCCTCTCAGGATTTGAAAATGAATATGATGTTATAggcggcggc
R:ctaggcggcggcggATATTGTAGTATAAGTAAAAGTTTAGGACTCTCCTATAATAGGTAACACTGTCTATAACGGTAT
204-252 F: atcgactagtggcggcggcggatccggcGTTGAAAAAGATGAAGCACAT
R: gctacggccatggcggcggcggcggTTCGTATAGAAAAAAGCA
33-G 115-150 F: gtcgactagtatgGCACAGGAAGGTATAAGTTAT
R: gctacggcctaggcggcggcggACTACTACCCTTGAAGAGGAA
204-252 F: atcgactagtggcggcggcggatccggcGTTGAAAAAGATGAAGCACAT
R: gctacggccatggcggcggcggcggTTCGTATAGAAAAAAGCA
33-H 75-97 F:CTAGTATGATATCCTCAAATGAATACATTATTGAAGATTCATTTAAATTATTGAATTCAGAACAAAAAAACACACTTGGCGGCGGCG
R:ctaggTTCACACAAAAAAACAAGACTTAAGTTATTAAATTTACTTAGAAGTTATTACATAAGTAAACTCCTATA
204-252 F: atcgactagtggcggcggcggatccggcGTTGAAAAAGATGAAGCACAT
R: gctacggccatggcggcggcggcggTTCGTATAGAAAAAAGCA
33-I 7-11 GATAATATCCTCTCA
21-36 TATTTAAAACCCTTTAGCTGGAGTATATAGAAGCTTAAAAAAACAAATT
51-55 TTAAATTCACGTCTT
64-69 GTATTAGAATCTGATTTA
128-137 AAATATAAGGATGATTTAGAATCAATTAAA
159-180 GCAAAAACAGACGAACAAAAGAAGGAAAGTAAGTTCCTTCCATTTTTAACAAACATTGAGACCTTA
33-J 1-40 F:actagtatgGCAATATCTGTCACAATGGATAATATCCTCTCAGGATTTGAAAATGAATATGATGTTATA
R: gctacggcctaggcggcggcggTACAAAAAAAGTTAAACAAAA
204-252 F: atcgactagtggcggcggcggatccggcGTTGAAAAAGATGAAGCACAT
R: gctacggccatggcggcggcggcggTTCGTATAGAAAAAAGCA
33-K 183-252 F: actagtatgAACTTAGTTAATAAAATTGACGATTACTTAATT
R: gctacggccatggcggcggcggcggTTCGTATAGAAAAAAGCA
doi:10.1371/journal.pone.0024782.t002
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2.2 [52] on immunoblots when prepared under non-reducing
conditions. These same antibodies did not bind to the recombi-
nant subunit proteins when prepared under reducing conditions
(Figure 3). By ELISAs, conformational dependent mAb 5.2
reacted equally well with all eleven constructs as with MSP1-42
(data not shown). This suggests that all constructs retained similar
conformation as MSP1-42.
Immunogenicity of the truncated MSP1-42 subunit
proteins in mice
Secondary and tertiary sera from immunized Swiss Webster
mice were tested for antibodies specific for MSP1-19 by ELISA.
Responders were defined as having an ELISA O.D. of .0.2 at a
1/50 serum dilution. This value is greater than four-fold the O.D.
values observed for pre-immune mouse sera. As shown in
Figure 4A, the responsiveness to the immunogens varied from a
low 30–35% to a high percent response of 92%–100% after two
immunizations. In comparison, MSP1-19 had the lowest response
rate (18%) of all the constructs. Analysis of the tertiary sera,
however, revealed that an additional immunization (Figure 4A,
black bars) was able to increase the number of responders for the
majority of the constructs with the exception of Construct 33-C,
Construct 33-K, and MSP1-19. Construct 33-D – 33-I induced
response rates similar or comparable to the full length MSP1-42
(Figure 4A).
The immunogenicity of the truncated MSP1-42 proteins was
also evaluated in terms of MSP1-19 specific antibody titers. In
each of the antigen groups there were high and low responders
(Figure 4B). High responders were defined as having an ELISA
O.D. of .0.6 at a 1/1250 serum dilution. There were significant
differences in antibody titers across the vaccination groups (One-
way ANOVA [F(10, 133)=2.345, p=0.014]). Construct 33-D
induced significantly higher antibody titers than all other
truncated constructs (Tukey post-hoc comparison, p,0.05).
Regions of MSP1-33 influenced cytokine responses
Splenocytes of immunized mice were stimulated in vitro with the
immunogens and analyzed by IL-4/IFN-c ELISPOTS (Figure 5A
and B). For the purpose of analysis, constructs were separated into two
groups, Construct 33-A – 33-D and Constructs 33-E – 33-K, basing
o nt h ef a c tt h a tt h eC o n s t r u c tg r o u p3 3 - E–3 3 - Kd o e sn o tc o n t a i nT
cell epitopes within the 31 amino acid sequence immediately N-
terminal of the MSP1-19. Accordingly, Construct group 33-E – 33-K
induced significantly higher levels of IFNcthan Construct group 33-A
– 33-D (Logistic Regression for Repeated Measures, p,0.05). No
significant difference between the two groups was observed for the
production of IL-4. Thus, Constructs containing T cell epitopes
within the 31 amino acid sequence induced a skewed TH2 response
( F i g u r e5 A ) ;w h e r e a s ,t h o s ew i t h out this sequence induced a more
balanced TH1/TH2 response (Figure 5B). Constructs 33-J and 33-K
were not further studied since mouse data indicated that they did not
induce high responsiveness or immunogenicity.
Immunogenicity of the truncated MSP1-42 subunit
proteins in rabbits
Rabbit sera from quaternary bleeds were tested by ELISA for
MSP1-19 and MSP1-42 specific antibodies. All nine constructs were
able to induce an antibody response (Table 3). When antibody
endpoint titers were analyzed among the nine truncated MSP1-42
constructs, Construct 33-C induced the highest mean antibody titers
(geometric mean) against both MSP1-19 and MSP1-42; whereas,
Construct 33-F induced the lowest mean antibody titers.Construct 33-
D and 33-I had significantly lower mean antibody titers than MSP1-
42 (p=0.02 and p=0.0003; respectively). In addition, Construct 33-I
also had significantly lower titers than Construct 33-C (p=0.02).
In Vitro parasite growth inhibitory activity of truncated
anti-MSP1-42 antibodies
The ability of the rabbit sera generated by immunizations with
the truncated MSP1-42 constructs, formulated with ISA51, to
Figure 2. SDS-PAGE of the purified S2 cell expressed truncated MSP1-42 proteins. Expected molecular sizes of each construct are in
parenthesis. Lane 1: Construct 33-A (19 kDa); Lane 2: Construct 33-B (21 kDa); Lane 3: Construct 33-C (14 kDa); Lane 4: Construct 33-D (29 kDa); Lane
5: Construct 33-E (32 kDa); Lane 6: Construct 33-F (39 kDa); Lane 7: Construct 33-G (21 kDa); Lane 8: Construct 33-H (19 kDa); Lane 9: Construct 33-I
(17 kDa); Lane 10: Construct 33-J (21 kDa); Lane 11: Construct 33-K (19 kDa).
doi:10.1371/journal.pone.0024782.g002
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[20,32,48,49]. Inhibition greater than 50% is considered to be
biologically significant [19,53,54]. As shown in Table 3, there were
constructs which induced no significant inhibitory antibodies in
the immunized rabbits (Construct 33-C and 33-G). There were
constructs with which one or two of the three immunized animals
produced significant levels of inhibitory antibodies (Construct 33-
A, 33-B, 33-D, 33-E, 33-F, and 33-H). The positive control, full
length MSP1-42, had two out of three animals inducing significant
levels of inhibitory antibodies. Construct 33-D and 33-I were the
only two immunogens able to induce significant levels of inhibitory
antibody in three out of three animals (Table 3). The ability of
Construct 33-D and 33-I to induce inhibitory antibodies greater
than 50% in rabbits were found to be significant as compared to
other construct groups (Fisher Exact Test, two sided p-value
=0.0051) (Table 3). It is also important to emphasize that
Construct 33-C failed to induce significant inhibitory antibodies,
despite producing the highest mean antibody titers. On the other
hand, anti-Construct 33-I antibodies had the highest mean percent
parasite inhibition (76%) despite having ELISA titers that were at
least one log lower than those produced by Construct 33-C and
the full length MSP1-42 (p=0.02). To a lesser extent, Construct
33-D also induced significant parasite inhibition despite that fact
Figure 3. Truncated MSP1-42 proteins possess disulfide
sensitive conformation. Immunoblots of recombinant proteins
separated under reducing (lanes 1) and non-reducing (lanes 2)
conditions and probed with conformational sensitive anti-MSP1-19
monoclonal antibodies. Panel A: Construct 33-A – 33-C and MSP1-19
probed with mAb 12.8; Panel B: Constructs 33-A – 33-C and MSP1-19
probed with mAb 2.2; and Panel C: Constructs 33-A – 33-C and MSP1-19
probed with mAb 5.2 [47,48].
doi:10.1371/journal.pone.0024782.g003
Figure 4. ELISA antibody responses against MSP1-19 in Swiss
Webster mice immunized with recombinant truncated MSP1-
42 proteins. Panel A, percent responsiveness of mice immunized with
Constructs 33-A – 33-K after the first booster injection (grey) and after
the second booster injection (black). Panel B, antibody titers of mice
vaccinated with Constructs 33-A – 33-K. Results of tertiary bleeds are
shown. Horizontal bars indicate mean antibody titers. ANOVA (p,0.05)
indicated that the levels of antibody titers differed among groups.
Asterisk indicates a significant difference (Turkey post-hoc test, p,0.05)
between Construct 33-D and all other vaccination groups.
doi:10.1371/journal.pone.0024782.g004
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(p=0.02).
Anti-Construct 33-C antibodies interferes with inhibitory
anti-MSP1-42 antibodies
Non-inhibitory anti-Construct 33-C antibodies were tested for
interfering/blocking effects on inhibitory MSP1-42 sera. The
highly inhibitory MSP1-42 sera were obtained from previous
vaccination studies in which rabbits were hyper-immunized with
full length MSP1-42 emulsified in CFA [39]. The data in Table 4
demonstrates that when anti-MSP1-42 sera with high levels of
inhibitory activity, were mixed with anti-Construct 33-C sera from
two different rabbits (anti-Construct 33-C sera #1 and anti-
Construct 33-C sera #2) the levels of parasite growth inhibition
were reduced. MSP1-42 inhibitory serum #1 alone had an 86%
inhibition of parasite growth. The addition of anti-Construct 33-C
serum #1 to MSP1-42 inhibitory serum #1 decreased the parasite
growth inhibition from 86% to 59%. The addition of anti-
Construct 33-C serum #2 reduced growth inhibition from 86% to
73%. Similarly for MSP1-42 inhibitory serum #2, which alone
inhibited parasite growth at 93%, the level of p parasite inhibition
was reduced from 93% to 73% when anti-Construct 33-C serum
#1 was added; and from 93% to 89% when anti-Construct 33-C
serum #2 was added. The data also shows that anti-Construct 33-
C serum #1 had higher blocking/interfering activity than anti-
Construct 33-C serum #2. Mixing of normal rabbit serum with
the MSP1-42 inhibitory sera had negligible effects on parasite
inhibition.
Discussion
The development of recombinant MSP1-based malaria vaccines
to date has primarily focused on MSP1-42 and its C-terminal sub-
fragment, MSP1-19. The main purpose of this study is to examine
immune responses to the N-terminal sub-fragment of MSP1-42,
MSP1-33, in order to better understand its relevance and potential
in enhancing the immunogenicity and efficacy of MSP1-42 based
vaccines.
Previous studies have shown that MSP1-19 has limited ability in
inducing an antibody response in a genetically diverse host
population [31,33]. This is thought to be due to the scarcity of T
helper epitopes on MSP1-19 [29,31]. Although inclusion of
additional heterologous T cell epitopes may overcome this
limitation [55], such vaccines lack the advantage of priming
cognate T cell help that can be recalled during natural infections.
A number of T cell epitopes have already been identified on
MSP1-33 [28,29,30,56], and many of these epitopes were included
in the eleven recombinant subunit constructs described here.
Previous studies of these T cell epitopes have only focused on T
cell proliferation and/or cytokine production [28,29,30]. Whether
these epitopes can provide functional ‘‘help’’ to enhance anti-
MSP1-19 antibody responses have not been investigated. Our
results demonstrated that all truncated MSP1-33 fragments, when
fused to MSP1-19, were able to broaden the antibody respon-
siveness to MSP1-19 in outbred mice as compared to MSP1-19
alone. But the degree in broadening responsiveness varied among
the different fragments. A number of constructs were able to
induce a generalized response (80% -100% response rate), which
were comparable/equal to MSP1-42 (Figure 4A). This suggests
that some of the T cell epitope regions on MSP1-33 of P. falciparum
can provide adequate levels of helper function for the induction of
antibodies in a genetically diverse population. A previous study
with P. yoelii shows that MSP1-33 can provide help in the
induction of anti-MSP1-19 antibodies [57]. However, this study
only focused on Balb/c restricted haplotype and did not address
the ability to broaden the response in a population of diverse
MHC makeup. Our data provides for the first time, experimental
validation of the long-held assumption that MSP1-33 possesses T
helper epitopes that can enhance antibody responses specific for
MSP1-19 in a genetically diverse population.
Aside from providing T helper functions, our studies indicate
that the T cell epitope regions of MSP1-33 critically affected the
quality of the anti-MSP1-19 responses. This linkage of T cell help
to B cell specificity has been previously observed in a number of
studies [35,36,37,38] and more recently it has been extended to
large protein molecules [58]. One measurement of the specificity
of the anti-MSP1 antibody responses is their ability to inhibit
parasite growth in vitro. Accordingly, inclusion of certain T cell
epitope regions may contribute positively or negatively towards the
induction of inhibitory antibodies. As examples, Construct 33-D
and 33-I consistently induced high levels of parasite inhibitory
Figure 5. Induction of MSP1-specific IL-4 (grey bars) and IFN-c
(white bars) responses, as determined by ELISPOT, in mice
immunized with truncated MSP1-42 proteins. Panel A: Constructs
33-A – 33-D; Panel B: Constructs 33-E – 33-K. Horizontal bars indicate
mean SFU. Logistic Regression for Repeated Measures indicated that
IFNc levels were significantly higher (p,0.05) in Construct 33-E – 33-K
compared to Construct 33-A – 33-D. No significant difference was found
when comparing IL-4 levels. Mouse splenocytes were harvested 21 days
after the last immunization.
doi:10.1371/journal.pone.0024782.g005
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amount of inhibitory antibodies despite producing high antibody
titers. This suggests that the T cell epitope regions in Construct 33-
C were unable to focus antibody responses to inhibitory epitopes.
These inhibitory antibody responses observed are due to anti-
MSP1-19 antibodies since negligible anti-MSP1-33 antibodies
were induced (data not shown). Furthermore, the antibodies
induced by Construct 33-C interfered with the parasite inhibitory
activity of anti-MSP1-42 antibodies (Table 4). The MSP1-33
specific T cell epitope regions also influenced the relative balance
of TH1 versus TH2 responses. Inclusion of the 31 amino acid
sequence from Construct 33-C in other truncated MSP1-42
constructs had a tendency to bias response towards the TH2 arm
(Figure 5). Thus, based on our antibody and ELISPOT analyses
the T cell epitope regions contained in Construct 33-C would not
be beneficial because of their tendency to potentiate undesirable
antibody and T cell responses. The negative effects of these T cell
epitopes may be modulated by virtue of their relative dominance
Table 3. In vitro Parasite Growth Inhibition of Rabbit Anti-truncated MSP1-42 Sera.
Rabbit Sera (4
th Bleeds) % Parasite Growth Inhibition
a Reciprocal ELISA Antibody Titers
MSP1-42 Mean (Rbt#1-3±SD)
b MSP1-19 Mean (Rbt#1-3±SD)
b
Anti-33-A
d Rbt #1 75% 624,000 482,0006131,538 93,000 43,000637,233
Rbt #2 37% 361,000 23,000
Rbt #3 24% 498,000 36,000
Anti-33-B Rbt #1 66% 27,000 101,0006109,610 161,000 139,000620,133
Rbt #2 26% 156,000 137,000
Rbt #3 0% 245,000 121,000
Anti-33-C Rbt #1 10% 2,490,000 1,440,0006814,338 254,000 365,0006122,111
Rbt #2 32% 948,000 385,000
Rbt #3 22% 1,265,000 498,000
Anti-33-D
c Rbt #1 58% 93,000 218,0006450,617 43,000 146,0006269,367
Rbt #2 58% 125,000 133,000
Rbt #3 94% 889,000 548,000
Anti-33-E Rbt #1 31% 79,000 340,00062,957,000 27,000 111,00061,026,000
Rbt #2 71% 113,000 28,000
Rbt #3 53% 5,218,000 1,804,000
Anti-33-F
d Rbt #1 56% 137,000 55,000659,355 117,000 74,000641,053
Rbt #2 0% 54,000 93,000
Rbt #3 0% 22,000 37,000
Anti-33-G
d Rbt #1 0% 156,000 180,000658,774 202,000 220,000670,887
Rbt #2 0% 253,000 172,000
Rbt #3 0% 22,000 307,000
Anti-33-H
d Rbt #1 26% 110,000 169,000661,101 223,000 214,000621,362
Rbt #2 56% 190,000 190,000
Rbt #3 0% 230,000 230,000
Anti-33-I
cd Rbt #1 85% 125,000 133,000611,150 109,000 109,000611,015
Rbt #2 78% 146,000 121,000
Rbt #3 66% 129,000 99,000
Anti-MSP1-42 Rbt #1 60% 1,252,000 1,198,0006162,263 140,000 179,0006105,510
Rbt #2 0% 1,024,000 317,000
Rbt #3 56% 1,338,000 129,000
aMeans of two growth inhibition assays.
bGeometric mean and standard deviation of antibofy titers.
cFisher Exact Test, p,0.05.
dConsider titer significantly lower then MSP1-42 ((p=0.0021), 33-F(p=0.0195), 33-G(p=0.0004), 33-H(p=0.0003), 33-I(p=0.0003).
doi:10.1371/journal.pone.0024782.t003
Table 4. Anti-Construct 33-C Antibodies Interfere with
Inhibitory Anti-MSP1-42 Antibodies.
Serum Samples % Parasite Growth Inhibition
MSP1-42 Inhibitory Serum #1
alone 86%
+Normal Rabbit Serum 85%
+Anti-Construct 33-C Serum#1 59%
+Anti-Construct 33-C Serum#2 73%
MSP1-42 Inhibitory Serum #2
alone 93%
+ Normal Rabbit Serum 91%
+Anti-Construct 33-C Serum#1 73%
+Anti-Construct 33-C Serum#2 89%
doi:10.1371/journal.pone.0024782.t004
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outbred populations, and this could be the situation observed with
other constructs in our study. Since it is difficult to predict and/or
anticipate the relative dominance of T cell epitopes in a genetically
diverse population, it may be prudent to preemptively eliminate
the 33-C specific T cell epitopes from vaccine design in order to
avoid production of undesirable antibodies and T cell responses.
Accordingly, constructs such as 33-A, 33-B, and 33-D may
possibly be made more effective as an immunogen by eliminating
the T cell epitope regions found in Construct 33-C. Along the
same line, since the T cell epitopes within Construct 33-C and
Construct 33-I are recognized by humans from malaria endemic
populations [28,29,30], selective exclusion and/or inclusion of
these epitopes from a MSP1-42 based vaccine would ensure
boosting of only the desirable preexisting anti-MSP1 responses,
which in turn may enhance overall vaccine efficacy. Epidemio-
logical studies have provided evidence that protective immunity
afforded by MSP1 is dependent on the production of inhibitory
antibodies [5,59,60,61,62]. However, other studies have argued
the lack of correlation between anti-MSP1 inhibitory antibodies
Figure 6. Class II epitope prediction of the sequence of Construct 33-I by computer algorithm (Propred). Grey shaded sequences
represent motifs that may bind to Class II molecules.
doi:10.1371/journal.pone.0024782.g006
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MSP1-19 response may involve other immune effector mecha-
nisms such as Antibody Dependent Cell Cytotoxicity (ADCC),
which involves Fc-dependent killing of parasites through neutro-
phils and macrophages [65,66]. It is important to point out that
although the present study demonstrated the influence of MSP1-
33 specific T cell epitopes on the induction of parasite inhibitory
antibodies, it is possible that these T cell epitopes may have a
broader influence on the development of other protective anti-
MSP1-42 immune effector responses.
Recently, a prime-boost immunization regimen utilizing simian
adenoviral and poxviral vectors expressing four N-terminal
conserved blocks of MSP1 fused with both dimorphic forms of
MSP1-42 was reported as a new candidate malaria vaccine [67].
These vaccines were found to induce high antibody titers against
MSP1 and have high growth inhibitory activities [67]. The study
did not examine the contribution of MSP1-42 specific T cell
epitopes to the development of inhibitory antibodies. Further,
since the N-terminal regions (Blocks 1, 3, 5, 12) are physically
separated from MSP1-42 during merozoite development and
invasion it may be difficult for these regions to provide cognate
help in inducing or boosting antibody responses to MSP1-19.
Previous studies have also utilized non-MSP1 derived T cell
epitopes in conjunction with the MSP1-19 immunogen to
overcome genetic restrictions of MSP1-19 induced protection
[55]. The addition of these non-MSP1 T cell epitopes shows an
impact on antibody subclass and protective efficacy [55].
However, these epitopes will not be able to boost anti-MSP1-19
antibodies during natural infections. Our strategy of selective
inclusion of MSP1-33 T cell epitopes has the advantage of
boosting existing immunity to MSP1-42/MSP1-19 via cognate T
cell help in malaria exposed populations.
Our results provide a fresh glimpse on the manner by which
anti-MSP1-19 antibody response may be modulated during
natural infections where a full complement of MSP1-42 specific
T cell epitopes is presented. As example, dominant recognition of
T cell epitopes within Construct 33-C in malaria-exposed
individuals may skew responses toward the development of non-
inhibitory and/or interfering types of antibodies. It is tempting to
speculate that deployment of a full length MSP1-42 vaccine under
this setting, may not be able to potentiate the level(s) of protective
immunity and specificity observed with immunizations in naive
animal models [17,18,19,20]. Moreover, our results may also help
explain the lack of efficacy in a recent MSP1-42 clinical trial in
malaria endemic areas.
An important outcome of our study is the identification of a
more efficacious MSP1 vaccine than the current full length MSP1-
42; namely, Construct 33-I. Construct 33-I, along with Construct
33-D, were the only two immunogens able to induce significant
parasite growth inhibitory antibodies (.50%) in all immunized
rabbits; whereas all other vaccine groups including MSP1-42 failed
to do so. Importantly for Construct 33-I, the levels of parasite
inhibition were achieved at much lower antibody titers than what
were induced by MSP1-42. The prevailing view of an efficacious
MSP1-42 vaccine is the requirement of high antibody titers
needed for in vivo protection or in vitro parasite inhibition. This
would necessitate the use of powerful adjuvants to achieve the
desired immunogenicity. Our data with Construct 33-I indicates
that this truncated MSP1-42 vaccine can induce potent anti-
parasite antibodies at a much lower overall antibody response.
This would eliminate the prerequisite for strong adjuvants for its
deployment as a human malaria vaccine. An equally attractive
attribute of Construct 33-I is the sequence compositions of T cell
epitopes. First, the MSP1-33 specific T cell epitopes in this
construct are based entirely of conserved sequences, thereby
circumventing the potential complications of allelic variations.
Second, computer algorithm analyses of the T cell epitope
sequences revealed a promiscuous binding to all major HLA
Class II molecules (Figure 6), suggesting a potential broad immune
responsiveness that this vaccine can elicit in humans. The superior
immunological characteristics that Construct 33-I has over MSP1-
42 strongly justify further evaluations as a second generation
MSP1-42 based human malaria vaccine. To further validate the
vaccine candidacy of Construct 33-D and 33-I, it would be
necessary to perform immunogenicity and efficacy studies in non-
human primate models. Equally important is to evaluate whether
the T cell epitope regions defined by Construct 33-D and 33-I are
immunogenic in malaria exposed human populations; and
whether human T cells specific for these epitopes will be able to
provide necessary helper functions for the induction of protective
antibodies.
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